From the UK version of Wired, a passage about Esther Dyson suggesting we expedite the personalization of medicine, which will definitely happen, though no one knows when:

“‘They personalise my adverts, why can’t they personalise my medicine?’ Esther Dyson, serial investor and chairwoman of EDventures, uttered these words at London Web Summit, arguing that one of the greatest areas ripe for innovation for startups now is the healthcare sector.

Wired magazine editor David Rowan, interviewing Dyson at the conference on 1 March, pointed out that we don’t yet have personalised medicine because of the time and costs involved in human drug trials. This, says Dyson, should not stop us innovating, inventing and investing in products that will improve the general population’s health.

‘Most drugs are not totally effective for most of the population,,’ said Dyson. ‘They’re about 100 percent effective for 30 percent of the population and probably toxic for 20 percent. But if you know the genetics, drugs are going to be much better for the population.’

Five years from now, she argued, you won’t take serious medicine without knowing it’ll work for you. We will have moved away from trying and taking and hoping it will work — ‘currently,’ pointed out Dyson, ‘I get the same dose of a drug as 500 pound guy.'”